About this item:

722 Views | 277 Downloads

Author Notes:

Correspondence: M. Eric Gershwin, M.D., Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616; Telephone: +1-530-752-2884, Fax: +1-530-752-4669, Email: megershwin@ucdavis.edu.

Or to Junqi Niu, Department of Hepatology, First Hospital, University of Jilin, Changchun, 130021, China; Telephone: +86 431-8878-3891, Fax: +86-431-8561-2708, Email: junqiniu@yahoo.com.cn

Subject:

Research Funding:

This study was supported by grants from National Institutes of Health grant DK39588 and from the Eleventh Five-year Plan for AIDS and Viral Hepatitis (No. 2008ZX10002-004), Ministry of Health (No. 20073531), National Natural Science Foundation of China (No. 30771912 and 30972610), Grant-in-Aid for Scientific Research (C) and Grant-in-Aid for Research Activity start-up of Japan Society of the Promotion of Science KAKENHI (No. 21590433 and 22890024) and Jilin Province Science and Technology Agency (No. 200705128).

Keywords:

  • B cells
  • CD20
  • CD5
  • Primary biliary cirrhosis

Comparative analysis of portal cell infiltrates in AMA positive versus AMA negative PBC

Show all authors Show less authors

Tools:

Journal Title:

Hepatology

Volume:

Volume 55, Number 5

Publisher:

, Pages 1495-1506

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Substantial evidence supports dysregulated B cell immune responses in patients with primary biliary cirrhosis (PBC), including the presence of serum anti-mitochondrial antibodies (AMAs). However, recent reports from murine models of PBC suggest that B cells may also provide regulatory function and indeed the absence of B cells in such models leads to exacerbation of disease. The vast majority of patients with PBC have readily detectable antimitochondrial antibodies, but a minority (<5%), are AMA negative (AMA−) even with recombinant diagnostic technology. This issue prompted us to examine the nature of B cell infiltrates surrounding the portal areas in AMA positive (AMA+) and AMA− patients since they display indistinguishable clinical features. Of importance was the finding that the degree of bile duct damage around the portal areas was significantly milder in AMA+ PBC than those seen in AMA− PBC patients. The portal areas from AMA− patients had a significant increase of CD5+ cells infiltrating the ductal regions and the levels of B cell infiltrates were worse in the early phase of bile duct damage. The frequency of positive portal areas and the magnitude of CD5+ and CD20+ cellular infiltrates within areas of ductal invasion is associated with the first evidence of damage of biliary duct epithelia, but becomes reduced in the ductopenia stage, with the exception of CD5+ cells which remain sustained and predominate over CD20+ cells. In conclusion, our data suggest a putative role of B cell autoimmunity in regulating the portal destruction characteristic of PBC.

Copyright information:

© 2011 American Association for the Study of Liver Diseases

Export to EndNote